With Additional Active Ingredient Patents (Class 514/171)
-
Patent number: 11642293Abstract: A composition comprising at least two visually distinguishable phases, comprises at least one fatty phase with oil, at least one aqueous phase with hydrophilic gelling agent, and at least one compound chosen from N,N-dimethylglycine derivatives, alkyl(poly)glucosides, or a mixture thereof.Type: GrantFiled: October 25, 2017Date of Patent: May 9, 2023Assignee: L'OREALInventors: Xiaoying Hu, Runshuang Lu, Lingling Sun, Xiuxia Wang
-
Patent number: 11564902Abstract: An extended duration anesthetic includes a short duration local anesthetic in a dilute solution and a long duration local anesthetic. The long duration local anesthetic is maintained in a powdered form until the time of administration. Premeasured quantities of the dilute solution and powdered long duration local anesthetic in a kit allow for quick preparation of a solution with desired concentrations of both short duration local anesthetic and long duration local anesthetic at the time of administration.Type: GrantFiled: September 16, 2020Date of Patent: January 31, 2023Assignee: Ventis PharmaInventors: Jeremy Poulsen, Louis Stanfield, Lawrence Volz
-
Patent number: 11497746Abstract: The present disclosure relates to a pharmaceutical combination comprising (a) a histone deacetylase 6 inhibitor and (b) a programmed death ligand 1 (PD-L1) inhibitor, including combined preparations and pharmaceutical compositions thereof; uses of such combination in the treatment or prevention of cancer; and methods of treating or preventing cancer in a subject comprising administering a therapeutically effective amount of such combination.Type: GrantFiled: November 21, 2017Date of Patent: November 15, 2022Assignee: ACETYLON PHARMACEUTICALS, INC.Inventors: Steven Norman Quayle, Simon Stewart Jones, Teru Hideshima, Kenneth C. Anderson
-
Patent number: 11478417Abstract: An anhydrous and alcohol-free slow fragrance diffusive composition (lotion, gel or cream) with longer lasting properties than hydroalcoholic formula fragrance product that contains 50 to 75 percent by weight dimethicone crosspolymer gel, 0.01 to 30 percent by weight fragrance oil and 5 to 40 percent by weight volatile linear silicone fluid. Emollients may be added to moisturize the skin, improve the fragrance rendition and/or increase the miscibility of the fragrance oil in the composition when a high level of dimethicone is used (in case of a lotion for example). Moreover, a preservative and some pigments can be added to the formula to preserve the fragrant product from bacteria contamination and to improve the aesthetics respectively.Type: GrantFiled: April 3, 2020Date of Patent: October 25, 2022Assignee: AKI, Inc.Inventors: Mickael Devassine, Hrazhyna Devassine
-
Patent number: 11478530Abstract: The methods and assays described herein relate to the diagnosis, prognosis, and treatment of subjects with emphysema, COPD, and/or cigarette-induced lung damage. In some embodiments, the methods and assays relate to subjects with a decreased level of NLRX1 expression. In some embodiments, the methods and assays relate to the administration of an agonist of NLRX1 and/or an inhibitor of MAVS.Type: GrantFiled: August 9, 2018Date of Patent: October 25, 2022Assignees: BROWN UNIVERSITY, YALE UNIVERSITYInventors: Jack A. Elias, Chun Geun Lee, Min-Jong Kang
-
Patent number: 11478485Abstract: The present disclosure is drawn to compositions and methods for treating CNS disorders. In one embodiment, an oral pharmaceutical composition can comprise a therapeutically effective amount of pregn-4-ene-3,20-dione; and a pharmaceutically acceptable carrier that provides formation of either 3?-OH-5?-pregnan-20-one, or 3?-OH-5?-pregnan-20-one, or both in an amount sufficient to treat a CNS disorder when orally administered to a subject. In another embodiment, a method of treating a CNS disorder can comprise orally administering to a subject, a therapeutically effective amount of pregn-4-ene-3,20-dione that provides an amount of GABA receptor binding pregn-4-ene-3,20-dione metabolites that is sufficient to treat the CNS disorder.Type: GrantFiled: May 10, 2022Date of Patent: October 25, 2022Inventors: Mahesh V. Patel, Nachiappan Chidambaram, Kilyoung Kim, Kongnara Papangkorn, Benjamin J. Bruno, Kiran Kumar Vangara
-
Patent number: 11452732Abstract: This application is directed to a homogeneous solution of an aqueous, topical composition useful for the treatment of infection and/or for the treatment of inflammation due to trauma to tissue. Specifically, this application relates to a homogeneous, aqueous composition of a quinolone antibiotic and an anti-inflammatory agent.Type: GrantFiled: September 11, 2020Date of Patent: September 27, 2022Inventor: Randal Davis
-
Patent number: 11447565Abstract: The present invention relates to a method for treating a GD2 positive cancer by administering a preparation comprising an anti-GD2 antibody to a patient as a continuous intravenous infusion over 24 hours per day.Type: GrantFiled: September 11, 2017Date of Patent: September 20, 2022Assignee: APEIRON BIOLOGICS AGInventors: Hans Loibner, Manfred Schuster, Evelyne Janzek-Hawlat, Susanne Wiederkum, Bernhard Peball, Stefan Stranner, Oliver Mutschlechner, Franz Groiss, Ruth Ladenstein, Holger Lode
-
Patent number: 11433082Abstract: An aqueous composition of latanoprost and SAE-CD is provided. The composition possesses improved stability over otherwise similar compositions excluding SAE-CD. Methods of and systems for treating disease, disorders, conditions or symptoms of the eye that are therapeutically responsive to latanoprost are also provided.Type: GrantFiled: November 1, 2019Date of Patent: September 6, 2022Assignee: CyDex Pharmaceuticals, Inc.Inventors: Naomi Esaki, James D. Pipkin
-
Patent number: 11413258Abstract: Disclosed herein are methods of inhibiting tumor growth or producing tumor regression in a subject by administering to the subject a therapeutically effective amount of a combination of palbociclib and RAD1901.Type: GrantFiled: September 24, 2019Date of Patent: August 16, 2022Assignee: Radius Pharmaceuticals, Inc.Inventor: Gary Hattersley
-
Patent number: 11389420Abstract: The present invention describes the use of a NK1-antagonist, in constant combination with neostigmine, to facilitate the treatment of a patient suffering from myasthenia gravis by providing a therapeutically effective neostigmine bromide or methylsulfate daily dose without the dose-limiting gastrointestinal adverse effects.Type: GrantFiled: January 24, 2020Date of Patent: July 19, 2022Assignee: DAS-MG, Inc.Inventor: Kathleen Clarence-Smith
-
Patent number: 11390654Abstract: Provided herein are treatment methods, including methods of treating nerve damage, methods of neuroprotection, methods of treating glaucoma and methods of lowering LDL levels. The methods generally involve administering to an individual in need thereof an effective amount of a CGRP receptor antagonist peptide or composition.Type: GrantFiled: August 30, 2017Date of Patent: July 19, 2022Inventor: Christopher Joseph Soares
-
Patent number: 11364198Abstract: Provided herein are compositions comprising an oil-in-water emulsion, wherein the emulsion comprises a liquid oil component; a cross-linked homopolymer based on acrylic acid and/or a cross-linked copolymer of acrylic acid and acrylic acid esters; and water. In some embodiments, the composition is a vehicle for the delivery of an active agent.Type: GrantFiled: April 5, 2019Date of Patent: June 21, 2022Assignee: BAUSCH HEALTH IRELAND LIMITEDInventors: Arturo Angel, Chandelle Hermes
-
Patent number: 11344531Abstract: The invention relates to an aqueous melatonin composition exhibiting surprising long-term stability and allowing high concentrations of said water-insoluble active ingredient. The properties of said composition render it useful as an injectable, for example, for the intravenous administration thereof.Type: GrantFiled: March 27, 2015Date of Patent: May 31, 2022Assignees: Servicio Andaluz de Salud, Universidad de GranadaInventors: Darío Acuña Castroviejo, Germaine Escames Rosa, Pablo Bueno Laraño, Alfonso Mansilla Roselló, José Antonio Ferrón Orihuela, José Jorge Hernández Magdalena, Miguel Ángel Calleja Hernández, Desirée González Callejas, Ana Comino Pardo, Carmen Olmedo Martín, Carmen Venegas Maldonado
-
Patent number: 11337987Abstract: The present disclosure is drawn to compositions and methods for treating CNS disorders. In one embodiment, an oral pharmaceutical composition can comprise a therapeutically effective amount of pregn-4-ene-3,20-dione; and a pharmaceutically acceptable carrier that provides formation of either 3?-OH-5?-pregnan-20-one, or 3?-OH-5?-pregnan-20-one, or both in an amount sufficient to treat a CNS disorder when orally administered to a subject. In another embodiment, a method of treating a CNS disorder can comprise orally administering to a subject, a therapeutically effective amount of pregn-4-ene-3,20-dione that provides an amount of GABA receptor binding pregn-4-ene-3,20-dione metabolites that is sufficient to treat the CNS disorder.Type: GrantFiled: May 7, 2021Date of Patent: May 24, 2022Inventors: Mahesh V. Patel, Nachiappan Chidambaram, Kilyoung Kim, Kongnara Papangkorn, Benjamin J. Bruno, Kiran Kumar Vangara
-
Patent number: 11332494Abstract: An oxysterol or oxysterol-like compound is provided, which finds use in treating and/or targeting cancer.Type: GrantFiled: April 25, 2017Date of Patent: May 17, 2022Assignee: Fernando Thome KreutzInventor: Fernando Thome Kreutz
-
Patent number: 11324772Abstract: The present invention relates to a periodontal gel composition, more particularly to a liquid composition having a low viscosity at ambient temperature, which upon warming to body temperature solidifies into a viscous gel and then releases a therapeutic agent, e.g., an antibacterial agent, in a sustained release manner; and to a method of use.Type: GrantFiled: February 27, 2018Date of Patent: May 10, 2022Assignee: PRUDENTIX LTD.Inventors: Keren Mevorat Kaplan, Dadi Segal, Danny Rosenbaum, Igal Liapis, Igor Makarovsky, Meir Stern
-
Patent number: 11324694Abstract: A method of making a pharmaceutical composition for delivery to the lower respiratory tract via nebulization within a sterile diluent includes mixing dry powder ingredients including a beta agonist or anticholinergic and one or more additional ingredients to formulate a dry powder mixture for mixing with the sterile diluent.Type: GrantFiled: October 28, 2021Date of Patent: May 10, 2022Assignee: CMPD Licensing, LLCInventor: Jay Richard Ray, II
-
Patent number: 11304960Abstract: Provided herein are steroid containing compositions suitable for providing therapeutically effective amounts of at least one steroid to individuals. Also provided herein are compositions comprising testosterone and/or testosterone derivatives suitable for providing therapeutically effective and safe amounts of testosterone over periods of time. Further provided are methods of treating andro- and/or testosterone deficiency in individuals by administering to the individuals compositions described herein.Type: GrantFiled: January 8, 2009Date of Patent: April 19, 2022Inventors: Chandrashekar Giliyar, Nachiappan Chidambaram, Mahesh V. Patel, Srinivasan Venkateshwaran
-
Patent number: 11299497Abstract: The present invention relates to novel substituted tetrahydropyran dihydrothienopyrimidines with phosphodiesterase inhibitory activity, and to their use in therapy, and to pharmaceutical compositions comprising the compounds and to methods of treating diseases with the compounds (I).Type: GrantFiled: December 14, 2018Date of Patent: April 12, 2022Assignee: UNION therapeutics A/SInventors: Jens Larsen, Simon Feldbaek Nielsen, Peter Andersen
-
Patent number: 11292799Abstract: The present invention relates to novel substituted azetidine dihydrothienopyrimidines with phosphodiesterase inhibitory activity, and to their use in therapy, and to pharmaceutical compositions comprising the compounds and to methods of treating diseases with the compounds (I).Type: GrantFiled: December 14, 2018Date of Patent: April 5, 2022Assignee: UNION THERAPEUTICS A/SInventors: Mark Andrews, Daniel Rodriguez Greve, Jens Larsen
-
Patent number: 11266663Abstract: Described herein are neurosteroids and analogues thereof and derivatives thereof, including, but not limited to, allopregnanolone, allopregnanolone analogues, and derivatives thereof that can be used for treatment of a neuropsychiatric disorder and/or symptom thereof. Also described herein are pharmaceutical formulations containing an effective amount of a neurosteroids and analogues thereof and derivatives thereof, where the effective amount can be effective for treating a neuropsychiatric disorder and/or symptom thereof. Also described herein are methods of treating a neuropsychiatric disorder and/or a symptom thereof in a subject in need thereof.Type: GrantFiled: June 22, 2018Date of Patent: March 8, 2022Assignee: The Board of Trustees of the University of IllinoisInventors: Graziano Pinna, Andrea Locci
-
Patent number: 11268952Abstract: The present invention relates to the discovery that certain non-naturally occurring, non-peptide amide compounds and amide derivatives, such as oxalamides, ureas, and acrylamides, are useful flavor or taste modifiers, such as a flavoring or flavoring agents and flavor or taste enhancer, more particularly, savory (the “umami” taste of monosodium glutamate) or sweet taste modifiers, savory or sweet flavoring agents and savory or sweet flavor enhancers, for food, beverages, and other comestible or orally administered medicinal products or compositions.Type: GrantFiled: January 16, 2020Date of Patent: March 8, 2022Assignee: Firmenich IncorporatedInventors: Catherine Tachdjian, Andrew P. Patron, Sara L. Adamski-Werner, Farid Bakir, Qing Chen, Vincent Darmohusodo, Stephen Terrence Hobson, Xiaodong Li, Ming Qi, Daniel H. Rogers, Marketa Rinnova, Guy Servant, Xiao-Qing Tang, Mark Zoller, David Wallace, Amy Xing, Klaus Gubernator
-
Patent number: 11260062Abstract: Provided is a composition for treating or ameliorating lung cancer including a glucocorticoid-based compound, a glucocorticoid-based compound and an mTOR inhibitor, or a glucocorticoid-based compound and an AMPK inhibitor as an active ingredient. The glucocorticoid-based compounds inhibit the growth of cancer cells by suppressing NRF2 in KEAP1 mutant lung cancer or KEAP1 and LKB1 mutant lung cancer, and exhibit a more potent anticancer effect when used in combination with the mTOR inhibitor, and thus the compounds can be effectively used as anticancer agents for mutant lung cancer. Further, the glucocorticoid-based compounds exhibit a strong anticancer synergistic effect in a low nutritional state when treated in combination with an AMPK inhibitor in KEAP1 and LKB1 normal lung cancer, and thus the compounds can also be used as an anticancer agent for KEAP1 normal lung cancer.Type: GrantFiled: November 2, 2016Date of Patent: March 1, 2022Assignee: AJOU UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATIONInventor: Sang-Min Jeon
-
Patent number: 11241426Abstract: Provided is an aqueous composition for ophthalmic or nasal administration comprising levocetirizine or its salt. In one embodiment, the composition comprises levocetirizine or its salt at a levocetirizine concentration of 0.05-0.5% (w/v). The composition may further comprise a surface active agent and/or an organic acid salt.Type: GrantFiled: February 9, 2018Date of Patent: February 8, 2022Assignee: Nitto Medic Co., Ltd.Inventor: Mineo Onuki
-
Patent number: 11229655Abstract: The invention provides a fulvestrant composition comprising a pharmaceutically acceptable vehicle and not more than 2% total impurities and which, optionally, is free of a non-aqueous ester solvent. The composition may be used to treat hormone receptor positive metastatic breast cancer in a subject.Type: GrantFiled: January 23, 2019Date of Patent: January 25, 2022Assignee: Fresenius Kabi USA, LLCInventor: Jabar A. Faraj
-
Patent number: 11224575Abstract: The present invention concerns pharmaceutical formulations of ARN-509, which can be administered to a mammal, in particular a human, suffering from an androgen receptor (AR)-related disease or condition, in particular cancer, more in particular prostate cancer, including but not limited to castration-resistant prostate cancer, metastatic castration resistant prostate cancer, chemotherapy-naive metastatic castration resistant prostate cancer, biochemically relapsed hormone sensitive prostate cancer, or high-risk, non-metastatic castration-resistant prostate cancer. In one aspect, these formulations comprise a solid dispersion of ARN-509, a poly(meth)acrylate copolymer and HPMCAS. In one aspect, the solid dispersion of ARN-509, a poly(meth)acrylate copolymer and HPMCAS is obtainable, in particular is obtained, by melt-extruding a mixture comprising ARN-509, a poly(meth)acrylate copolymer and HPMCAS and optionally subsequently milling said melt-extruded mixture.Type: GrantFiled: March 19, 2019Date of Patent: January 18, 2022Assignee: Aragon Pharmaceuticals, Inc.Inventor: Geert Verreck
-
Patent number: 11197822Abstract: Provided herein are methods for preventing or alleviating the symptoms of and inflammation associated with inflammatory diseases and conditions of the gastrointestinal tract, for example, those involving the esophagus. Also provided herein are pharmaceutical compositions useful for the methods of the present invention.Type: GrantFiled: March 11, 2019Date of Patent: December 14, 2021Assignees: The Regents of the University of California, Meritage Pharma, Inc.Inventors: Ranjan Dohil, John Bastian, Seema Aceves, Elaine Phillips, Malcolm Hill
-
Patent number: 11180488Abstract: The present invention provides compounds of Formula (Ia) or (Ib) or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein X1, X2, X3, and X4 are each independently CR6 or N; provided that no more than two of X1, X2, X3, or X4 are N; L is C1-4 alkylene substituted with 0 to 4 R7; R1 is (—CH2)aR9; a is an integer of 0 or 1; R2 is each independently halo, cyano, hydroxyl, amino, C1-6 alkyl, C3-6 cycloalkyl, C4-6 heterocyclyl, alkylamino, haloalkyl, hydroxyalkyl, aminoalkyl, alkoxy, alkoxyalkyl, haloalkoxyallcyl, or haloalkoxy; n is an integer of 0, 1, or 2; R3 is hydrogen, C1-6 alkyl, C1-6 deuterated alkyl, haloalkyl, hydroxyalkyl, aminoalkyl, alkoxyalkyl, haloalkoxyalkyl, alkoxy, or haloalkoxy, and the alkyl, by itself or as part of other moiety, is optionally substituted with deuterium partially or fully; R4 is C1-10 alkyl, C1-10 deuterated alkyl, C1-10 haloalkyl, C1-10 alkenyl, C3-8 cycloalkyl, 6 to 10-membered aryl, 3 to 8-membered heterocyclyl, —(C1-6 alkylene)-(C3-8 cyclType: GrantFiled: December 18, 2018Date of Patent: November 23, 2021Inventors: Peter Tai Wah Cheng, Robert F. Kaltenbach, III, Hao Zhang, Yan Shi, Jun Li
-
Patent number: 11166978Abstract: The present invention provides a synergistic anti-inflammatory composition comprising one more anti-inflammatory agents such as a steroid, non-steroidal anti-inflammatory drug (NSAID) or a cannabinoid in combination with one or more sulfated polysaccharides. The invention is further directed to a method of treating inflammation and inflammatory diseases using said synergistic composition.Type: GrantFiled: July 30, 2020Date of Patent: November 9, 2021Assignee: Seanergy Dermatology Ltd.Inventor: Doron Friedman
-
Patent number: 11154527Abstract: A composition and method for the prophylaxis and treatment of topical fungal infections is provided. Generally, the composition includes an HMG-CoA reductase inhibitor and a carrier. In some forms, the composition further includes an anti-fungal agent. The method generally includes the steps of applying the composition topically once or multiple times. The composition and method can be used in combination with another form of fungal treatment, such as oral medications.Type: GrantFiled: August 26, 2019Date of Patent: October 26, 2021Assignee: The Children's Mercy HospitalInventors: Susan Abdel-Rahman, Barry L. Preuett, J. Steven Leeder
-
Patent number: 11154528Abstract: An extended duration anesthetic includes a short duration local anesthetic in a dilute solution and a long duration local anesthetic. The long duration local anesthetic is maintained in a powdered form until the time of administration. Premeasured quantities of the dilute solution and powdered long duration local anesthetic in a kit allow for quick preparation of a solution with desired concentrations of both short duration local anesthetic and long duration local anesthetic at the time of administration.Type: GrantFiled: October 1, 2018Date of Patent: October 26, 2021Assignee: Ventis PharmaInventors: Jeremy Poulsen, Louis Stanfield, Lawrence Volz
-
Patent number: 11123323Abstract: The invention relates to the combined use of at least one monoterpene which can be applied systemically, in particular perorally, and at least one respiratory tract therapeutic agent which can be applied topically, in particular through inhalation, for the prophylactic and/or therapeutic treatment, in particular combination therapy and/or co-medication, of respiratory tract diseases, in particular bronchopulmonary diseases. Through the combined use of the systemic monoterpene with the topical, in particular inhaled respiratory tract therapeutic agent, the effect or efficiency of the topical or inhaled respiratory disease therapeutic agent can be increased significantly, in particular in a synergistic manner, on the one hand, and the required dosage thereof can be reduced significantly on the other hand, combined with the resulting advantages (e.g., avoidance or reduction of side effects).Type: GrantFiled: July 15, 2016Date of Patent: September 21, 2021Assignee: MARIA CLEMENTINE MARTIN KLOSTERFRAU VERTRIEBSGESELLSCHAFT MBHInventor: Harald Greve
-
Patent number: 11124537Abstract: The present invention relates generally to compositions and methods for treating cancer and hypercortisolism. Provided herein are substituted steroidal derivative compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for inhibition of glucocorticoid receptors. Furthermore, the subject compounds and compositions are useful for the treatment of cancer and hypercortisolism.Type: GrantFiled: December 22, 2016Date of Patent: September 21, 2021Assignee: ORIC PHARMACEUTICALS, INC.Inventors: Daqing Sun, Lawrence R. McGee, Xiaohui Du, Liusheng Zhu, Xuelei Yan, Yosup Rew, John Eksterowicz, Julio C. Medina, Haiying Zhou, Minna Delarae Balbas, Valeria R. Fantin
-
Patent number: 11103510Abstract: This disclosure relates to JAK1 pathway inhibitors and the use thereof in treating cytokine-related diseases or disorders such as cytokine release syndrome (CRS), hemophagocytic lymphohistiocytosis (HLH), macrophage activation syndrome (MAS), and CAR-T-cell-related encephalopathy syndrome (CRES).Type: GrantFiled: February 14, 2019Date of Patent: August 31, 2021Assignee: Incyte CorporationInventors: Michael O'Neill Montgomery, Ahmad Naim, Susan Snodgrass
-
Patent number: 11091437Abstract: The present invention provides aryl isonitrile compounds that have antibacterial properties. More specifically, the aryl isonitrile compounds of the present invention are potent inhibitors of drug resistant strains of Staphylococcus aureus.Type: GrantFiled: June 18, 2019Date of Patent: August 17, 2021Assignee: Purdue Research FoundationInventors: Mohamed Seleem, Mingji Dai, Dexter Cameron Davis, Haroon Taj Mohammad
-
Patent number: 11083737Abstract: The disclosure provides a deflazacort therapy comprising, administering to a subject suffering from Duchenne muscular dystrophy (DMD) a fixed dose of deflazacort. Also provided is a deflazacort therapy comprising, increasing the deflazacort dosage when the subject loses ambulation; or, increasing the dosage of deflazacort administered during concomitant administration of a CYP3A4 inducer; or, decreasing the dosage of deflazacort administered during concomitant administration of a CYP3A inhibitor.Type: GrantFiled: May 26, 2017Date of Patent: August 10, 2021Assignee: PTC THERAPEUTICS, INC.Inventors: Stephen P. Wanaski, Virginia D. Schmith, Linda L. Grasfeder, Scott Joseph Brantley
-
Patent number: 11061027Abstract: This document provides methods and materials for detecting PCA-2-specific autoantibodies, which can be associated with paraneoplastic neurological disorders and cancers associated with PCA-2-specific autoantibodies.Type: GrantFiled: September 12, 2017Date of Patent: July 13, 2021Assignee: Mayo Foundation for Medical Education and ResearchInventors: Sean J. Pittock, Thomas J. Kryzer, Avi Gadoth, Andrew McKeon, Vanda A. Lennon, James P. Fryer
-
Patent number: 11052084Abstract: The present disclosure relates to pharmaceutical capsules comprising lumateperone, in free, or pharmaceutically acceptable salt form, optionally in combination with one or more additional therapeutic agents, processes for manufacture thereof and methods of use in the treatment or prophylaxis of disease.Type: GrantFiled: June 16, 2020Date of Patent: July 6, 2021Assignee: INTRA-CELLULAR THERAPIES, INC.Inventors: Peng Li, Robert Davis
-
Patent number: 11026920Abstract: The invention relates to methods for treating pruritus with NK-1 receptor antagonists such as serlopitant. The invention further relates to pharmaceutical compositions comprising NK-1 receptor antagonists such as serlopitant. In addition, the invention encompasses treatment of a pruritus-associated condition with serlopitant and an additional antipruritic agent, and the use of serlopitant as a sleep aid, optionally in combination with an additional sleep-aiding agent.Type: GrantFiled: March 2, 2020Date of Patent: June 8, 2021Assignee: VYNE THERAPEUTICS INC.Inventors: Xiaoming Zhang, Edward F. Schnipper, Andrew J. Perlman, James W. Larrick
-
Patent number: 11014880Abstract: This invention relates to compounds that are agonists of the muscarinic M1 receptor or M1 and M4 receptors and which are useful in the treatment of muscarinic M1 or M1/M4 receptor mediated diseases. Also provided are pharmaceutical compositions containing the compounds and the therapeutic uses of the compounds. Compounds provided are of formula wherein Q4, Q5, R5, p, V, Q1, Q2, X1, X2 and W are defined herein.Type: GrantFiled: June 2, 2020Date of Patent: May 25, 2021Assignee: Heptares Therapeutics LimitedInventors: Giles Albert Brown, Miles Stuart Congreve, Mark Pickworth, Benjamin Gerald Tehan
-
Patent number: 10968216Abstract: The present invention provides triazolone compounds of general formula (I): in which R1, R2, R3, R4 and R5 are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of hyperproliferative disorders, as a sole agent or in combination with other active ingredients.Type: GrantFiled: October 25, 2017Date of Patent: April 6, 2021Assignees: BAYER AKTIENGESELLSCHAFT, BAYER PHARMA AKTIENGESELLSCHAFT, THE BROAD INSTITUTE, INC., PRESIDENT AND FELLOWS OF HARVARD COLLEGE, THE GENERAL HOSPITAL CORPORATIONInventors: Stefan Nikolaus Gradl, Duy Nguyen, Knut Eis, Judith Günther, Timo Stellfeld, Andreas Janzer, Sven Christian, Thomas Mueller, Sherif El Sheikh, Han Jie Zhou, Changjia Zhao, David B. Sykes, Steven James Ferrara, Kery Liu, Simon Anthony Herbert, Claudia Merz, Michael Niehues, Carl Friedrich Nising, Martina Schäfer, Katja Zimmermann, Jörg Knäblein, Kai Thede, Thomas Faupel
-
Patent number: 10966930Abstract: The present invention concerns pharmaceutical formulations of ARN-509, which can be administered to a mammal, in particular a human, suffering from an androgen receptor (AR)-related disease or condition, in particular cancer, more in particular prostate cancer, including but not limited to castration-resistant prostate cancer, metastatic castration resistant prostate cancer, chemotherapy-naive metastatic castration resistant prostate cancer, biochemically relapsed hormone sensitive prostate cancer, or high-risk, non-metastatic castration-resistant prostate cancer. In one aspect, these formulations comprise a solid dispersion of ARN-509, a poly(meth)acrylate copolymer and HPMCAS. In one aspect, the solid dispersion of ARN-509, a poly(meth)acrylate copolymer and HPMCAS is obtainable, in particular is obtained, by melt-extruding a mixture comprising ARN-509, a poly(meth)acrylate copolymer and HPMCAS and optionally subsequently milling said melt-extruded mixture.Type: GrantFiled: March 19, 2019Date of Patent: April 6, 2021Assignee: Aragon Pharmaceuticals, Inc.Inventor: Geert Verreck
-
Patent number: 10925863Abstract: Described herein are methods for distributing a combination of a cell division inhibitor (e.g., temsirolimus or paclitaxel) and dexamethasone to a tissue surrounding a blood vessel for treating vascular diseases. Also disclosed are injectable compositions of a cell division inhibitor (e.g., temsirolimus or paclitaxel) and dexamethasone for delivery into the tissue surrounding a blood vessel for treating vascular diseases.Type: GrantFiled: October 2, 2019Date of Patent: February 23, 2021Assignee: MERCATOR MEDYSTEMS, INC.Inventor: Kirk Patrick Seward
-
Patent number: 10905668Abstract: The present invention relates to compounds of formula (I) and to pharmaceutical compositions containing them: wherein meanings of the substituents are indicated in the description. Such compounds for use in the treatment of cancer and other diseases related to altered angiogenesis, such as arthritic pathology, diabetic retinopathy, psoriasis and chronic inflammatory disease, are also within the scope of the present invention.Type: GrantFiled: September 28, 2017Date of Patent: February 2, 2021Assignee: BIOGEM S.C. A R.L.Inventors: Claudio Pisano, Sabrina Dallavalle, Raffaella Cincinelli, Lucio Merlini
-
Patent number: 10898495Abstract: Described herein are methods of promoting remyelination in a subject suffering from demyelination diseases by administering to the subject a combination of steroid hormones and Hedgehog signaling pathway modulators. Also described are methods of administering the combination of drugs, wherein the combination of drugs are in compositions adapted for nasal administration.Type: GrantFiled: March 11, 2020Date of Patent: January 26, 2021Assignee: M ET P PHARMA AGInventors: Claudia Mattern, Elisabeth Traiffort, Michael Schumacher
-
Patent number: 10874638Abstract: Provided herein are compositions and methods for the treatment of androgen and estrogen receptors mediated conditions.Type: GrantFiled: September 16, 2019Date of Patent: December 29, 2020Assignee: Ligand Pharmaceuticals IncorporatedInventor: Lin Zhi
-
Patent number: 10849911Abstract: The present invention relates to salts of arachidyl amido cholanoic acid (Aramchol), pharmaceutical compositions comprising Aramchol salts, methods for their preparation, and methods of use thereof in medical treatment.Type: GrantFiled: June 8, 2016Date of Patent: December 1, 2020Assignee: Galmed Research and Development Ltd.Inventors: Allen Baharaff, Idit Eshkar-Oren
-
Patent number: 10835502Abstract: This disclosure relates to a method of reducing a fat deposit comprising injecting an alcohol-containing pharmaceutical composition into the fat deposit. The method may be effective in improving the appearance of or reducing the weight or volume of the fat deposit.Type: GrantFiled: October 15, 2019Date of Patent: November 17, 2020Assignee: Polithera, Inc.Inventors: Adam M. Rotunda, Vince Afsahi
-
Patent number: 10837971Abstract: Methods are provided for detecting the amount of one or more HRT panel analytes (i.e., estrone (E1), estrone sulfate (E1s), 17?-estradiol (E2a), 17?-estradiol (E2b), estradiol sulfate (E2s), estriol (E3), equilin (EQ), 17?-dihydroequilin (EQa), 17?-dihydroequilin (EQb), Equilenin (EN), 17?-dihydroequilenin (ENa), 17?-dihydroequilenin (ENb), and ?8,9-dehydroestrone (dE1)) in a sample by mass spectrometry. The methods generally involve ionizing one or more HRT panel analytes in a sample and quantifying the generated ions to determine the amount of one or more HRT panel analytes in the sample. In methods where amounts of multiple HRT panel analytes are detected, the amounts of multiple analytes are detected in the same sample injection.Type: GrantFiled: August 30, 2016Date of Patent: November 17, 2020Assignee: Quest Diagnostics Investments IncorporatedInventors: Mildred Goldman, Nigel Clarke